Sandra Algaze
Overview
Explore the profile of Sandra Algaze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, et al.
Int J Cancer
. 2024 Dec;
156(8):1583-1593.
PMID: 39740007
Myeloid cell leukemia 1 (MCL-1) is a member of the B-cell lymphoma 2 protein family and has anti-apoptotic functions. Deregulation of MCL-1 has been reported in several cancers, including lung...
2.
Arai H, Gandhi N, Battaglin F, Wang J, Algaze S, Jayachandran P, et al.
J Immunother Cancer
. 2024 Nov;
12(11.
PMID: 39500526
Background: In patients with colorectal cancer (CRC), the therapeutic effects of conventional immune checkpoint inhibitors targeting the adaptive immune system are largely limited to those with microsatellite instability-high tumors. Meanwhile,...
3.
Ashouri K, Wong A, Mittal P, Torres-Gonzalez L, Lo J, Soni S, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199569
Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors have significantly improved patient outcomes, their effectiveness is mostly limited to tumors with microsatellite...
4.
Morgenstern-Kaplan D, Kareff S, Trabolsi A, Rodriguez E, Krause H, Ribeiro J, et al.
Oncologist
. 2024 Jul;
29(11):e1480-e1491.
PMID: 38986529
Background: TROP2 (TACSTD2) expression is associated with decreased overall survival (OS) in some solid tumors, and the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan has been approved in breast and urothelial...
5.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou F, et al.
Eur J Cancer
. 2024 Feb;
201:113914.
PMID: 38359495
Background: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic...
6.
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38212126
Background: The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated...
7.
Jayachandran P, Battaglin F, Strelez C, Lenz A, Algaze S, Soni S, et al.
Oncogene
. 2023 Jan;
42(9):627-637.
PMID: 36650218
Exploring the relationship between various neurotransmitters and breast cancer cell growth has revealed their likely centrality to improving breast cancer treatment. Neurotransmitters play a key role in breast cancer biology...
8.
Battaglin F, Jayachandran P, Strelez C, Lenz A, Algaze S, Soni S, et al.
Oncogene
. 2022 Oct;
41(43):4769-4778.
PMID: 36182970
The brain-gut axis, a bidirectional network between the central and enteric nervous system, plays a critical role in modulating the gastrointestinal tract function and homeostasis. Recently, increasing evidence suggests that...
9.
Piatek C, Bocian H, Algaze S, Weitz I, OConnell C, Liebman H
Acta Haematol
. 2019 Oct;
143(3):244-249.
PMID: 31665725
The combination of rituximab, cyclophosphamide, and dexamethasone (RCD) is highly effective in the treatment of warm autoimmune hemolytic anemia (WAIHA) associated with chronic lymphocytic leukemia (CLL). We treated a cohort...
10.
Ali R, Ramdial J, Algaze S, Beitinjaneh A
Biomedicines
. 2017 Nov;
5(4).
PMID: 29186076
Allogeneic hematopoietic stem cell transplant is an established treatment modality for hematologic and non-hematologic diseases. However, it is associated with acute and long-term sequelae which can translate into mortality. Graft-versus-host...